Share: Facebook Twitter LinkedIn
Activity Provided By:

University of Cincinnati

PARP Inhibition as Ovarian Cancer Maintenance Therapy: Improving Patient Outcomes as a Multidisciplinary Team

Access Activity

Overview / Abstract:

Ovarian cancer (OC) is often diagnosed at an advanced stage and has generally poor survival rates¬"even after aggressive surgical management and chemotherapy. Without maintenance therapy, approximately 70% of patients relapse within 3 years of treatment. Recent clinical trials of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors have demonstrated substantial efficacy as maintenance therapy for OC patients. Additionally, clinical evidence suggests that daily monitoring of patients receiving maintenance therapy by a multidisciplinary team is essential to treatment success and a better quality of life. However, studies have also shown that a number of practice gaps continue to compromise OC patient care, including failure to offer PARP inhibitors as maintenance therapy, low confidence in managing the adverse events (AEs) associated with PARP inhibitor therapy, and inconsistencies in the delivery of guideline-directed care and multidisciplinary management.

This activity has been developed to review guideline-recommended PARP inhibitor maintenance therapies for patients with OC and to provide strategies for effectively managing treatment-related AEs.


Oct 25, 2024


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME



Credits / Hours

0.5 AMA PRA Category 1 Credit



Presenters / Authors / Faculty

Michael J. Birrer, MD, PhD
Director, Winthrop P. Rockefeller Cancer Institute
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Ursula A. Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sponsors / Supporters / Grant Providers

Support for this activity has been provided through educational grants from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme Corp.

Keywords / Search Terms

RedMedEd RedMedEd, PARP, Ovarian cancer, ovarian, maintenance therapy, patient, patient outcomes, multidisciplinary, chemo, chemotherapy, advanced stage, survival rates, relapse, clinical trials, clinical evidence, monitoring, inhibitors, PARP inhibitors, CME, Free, CE, polyadenosine diphosphate-ribose polymerase, PARP inhibitor therapy, adverse events, AEs, strategies, treatment, guideline, guidelines, review Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map